Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial
Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain…